New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...
Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...
Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. Third quarter 2025 results will ...
Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...
Sanofi en discussions pour céder une participation majoritaire dans Opella Paris, 11 octobre 2024. Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession ...
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...
The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.
Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...
100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.
Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...
L’hémophilie est une affection rare, héréditaire, à vie dans laquelle le sang d’une personne ne coagule pas correctement en raison d’un manque de protéines appelées facteurs de coagulation. Par ...
100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...